Strongbridge Biopharma (NASDAQ:SBBP) – Equities researchers at Cantor Fitzgerald decreased their FY2018 earnings estimates for Strongbridge Biopharma in a report released on Tuesday, March 13th, Zacks Investment Research reports. Cantor Fitzgerald analyst E. Piros now expects that the biotechnology company will earn ($1.38) per share for the year, down from their prior forecast of ($1.23). Cantor Fitzgerald currently has a “Buy” rating and a $14.00 target price on the stock.
Several other brokerages have also recently weighed in on SBBP. BidaskClub raised shares of Strongbridge Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 11th. Zacks Investment Research raised shares of Strongbridge Biopharma from a “sell” rating to a “hold” rating in a research report on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Strongbridge Biopharma in a research report on Thursday, January 18th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. Strongbridge Biopharma presently has a consensus rating of “Buy” and an average price target of $12.81.
NASDAQ SBBP traded down $0.70 during trading hours on Friday, hitting $7.60. The company’s stock had a trading volume of 368,578 shares, compared to its average volume of 288,662. Strongbridge Biopharma has a 52 week low of $3.50 and a 52 week high of $9.25. The stock has a market cap of $345.87, a price-to-earnings ratio of -5.24 and a beta of 0.99. The company has a debt-to-equity ratio of -3.17, a quick ratio of 4.84 and a current ratio of 4.88.
Strongbridge Biopharma (NASDAQ:SBBP) last announced its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.34) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.34). The business had revenue of $2.98 million during the quarter, compared to the consensus estimate of $2.98 million.
A number of large investors have recently bought and sold shares of SBBP. 683 Capital Management LLC purchased a new stake in shares of Strongbridge Biopharma during the 4th quarter worth approximately $1,450,000. Lyon Street Capital LLC increased its stake in shares of Strongbridge Biopharma by 239.0% during the 4th quarter. Lyon Street Capital LLC now owns 1,406,095 shares of the biotechnology company’s stock worth $10,194,000 after purchasing an additional 991,322 shares during the last quarter. Paloma Partners Management Co purchased a new stake in shares of Strongbridge Biopharma during the 4th quarter worth approximately $152,000. Perceptive Advisors LLC purchased a new stake in shares of Strongbridge Biopharma during the 4th quarter worth approximately $1,994,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Strongbridge Biopharma during the 4th quarter worth approximately $272,000. Hedge funds and other institutional investors own 57.63% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/08/fy2018-eps-estimates-for-strongbridge-biopharma-plc-sbbp-reduced-by-analyst.html.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.
Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.